Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1069
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurphy, Declan-
dc.contributor.authorClouston, David-
dc.contributor.authorBolton, Damien-
dc.contributor.authorFrydenberg, Mark-
dc.contributor.otherPorter, Laura-
dc.contributor.otherLawrence, Mitchell-
dc.contributor.otherIlic, Dragan-
dc.contributor.otherPezaro, Carmel-
dc.contributor.otherRisbridger, Gail-
dc.contributor.otherTaylor, Renea-
dc.date.accessioned2017-05-05T03:19:17Z-
dc.date.available2017-05-05T03:19:17Z-
dc.date.issued2017-03-
dc.identifier.citationEur Urol. 2017 Mar 22. pii: S0302-2838(17)30178-1en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttp://hdl.handle.net/11434/1069-
dc.description.abstractIntraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, the prevalence of IDC-P remains unclear, with variable reports from small and disparate patient populations. To determine how common IDC-P is across the spectrum of prostate cancer, we conducted a systematic review correlating IDC-P prevalence with prostate cancer risk. Electronic searches of the OVID Medline, PubMed, and Scopus literature databases identified 38 patient cohorts in 24 articles, which were divided between four prostate cancer risk categories (low, moderate, high, and recurrent or metastatic disease). This review, which included radical prostatectomy and prostate biopsy specimens from >7000 patients, revealed an unexpectedly high rate of IDC-P. The IDC-P prevalence increased from 2.1% in low-risk patient cohorts to 23.1%, 36.7%, and 56.0% in moderate-risk, high-risk, and metastatic or recurrent disease risk categories, respectively (p<0.0001). IDC-P was also highly prevalent in tumours following androgen deprivation therapy or chemotherapy (60%). Contrary to common perceptions, this study demonstrates a strong association between IDC-P prevalence and aggressive prostate cancer, with a significantly higher frequency in high-risk disease. Greater recognition and systematic reporting of IDC-P may improve patient risk stratification. PATIENT SUMMARY: Prostate cancer can grow within ducts of the prostate, as well as in prostate tissue. By reviewing all reports describing prostate cancer growing within ducts, we found that it occurs more commonly than many scientists and clinicians appreciate, especially in aggressive prostate cancers. We conclude that there should be more awareness of this pattern of prostate cancer.en_US
dc.publisherElsevieren_US
dc.subjectBRCA2 Germline Mutationen_US
dc.subjectIntraductal Carcinoma of the Prostateen_US
dc.subjectPathologyen_US
dc.subjectProstate Canceren_US
dc.subjectRisk Stratificationen_US
dc.subjectIDC-Pen_US
dc.subjectPrognosisen_US
dc.subjectPrevalenceen_US
dc.subjectRadical Prostatectomyen_US
dc.subjectProstate Biopsy Specimensen_US
dc.subjectAndrogen Deprivation Therapyen_US
dc.subjectChemotherapyen_US
dc.subjectAggressive Prostate Cancersen_US
dc.subjectAustralian Prostate Cancer Research Centre Epworth HealthCare, Victoria, Australiaen_US
dc.subjectUroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleSystematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.eururo.2017.03.013en_US
dc.identifier.journaltitleEuropean Urologyen_US
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/28342640en_US
dc.description.affiliatesDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.en_US
dc.description.affiliatesProstate Cancer Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.en_US
dc.description.affiliatesSchool of Public Health & Preventive Medicine, Monash University, Melbourne, Australia.en_US
dc.description.affiliatesTissuPath, Mount Waverley, Australia.en_US
dc.description.affiliatesDepartment of Urology, Austin Hospital, Melbourne, Australia.en_US
dc.description.affiliatesDepartment of Surgery, University of Melbourne, Melbourne, Australia.en_US
dc.description.affiliatesDepartment of Surgery, Monash University, Melbourne, Australia.en_US
dc.description.affiliatesDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.en_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.en_US
dc.description.affiliatesEastern Health Clinical School, Monash University, Melbourne, Australia.en_US
dc.description.affiliatesDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.en_US
dc.type.studyortrialSystematic Reviewsen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
Epworth Prostate Centre
UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.